- Home
- TLSA vs AVTX Comparison
TLSA vs AVTX Comparison
Compare TLSA & AVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- AVTX
- Stock Information
- Founded
- TLSA 2013
- AVTX 2011
- Country
- TLSA United Kingdom
- AVTX United States
- Employees
- TLSA N/A
- AVTX N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- AVTX Biotechnology: Pharmaceutical Preparations
- Sector
- TLSA Health Care
- AVTX Health Care
- Exchange
- TLSA Nasdaq
- AVTX Nasdaq
- Market Cap
- TLSA 187.0M
- AVTX 57.4M
- IPO Year
- TLSA 2000
- AVTX 2015
- Fundamental
- Price
- TLSA $1.45
- AVTX $4.89
- Analyst Decision
- TLSA
- AVTX Strong Buy
- Analyst Count
- TLSA 0
- AVTX 7
- Target Price
- TLSA N/A
- AVTX $31.00
- AVG Volume (30 Days)
- TLSA 246.7K
- AVTX 82.2K
- Earning Date
- TLSA 07-22-2025
- AVTX 08-11-2025
- Dividend Yield
- TLSA N/A
- AVTX N/A
- EPS Growth
- TLSA N/A
- AVTX N/A
- EPS
- TLSA N/A
- AVTX N/A
- Revenue
- TLSA N/A
- AVTX $441,000.00
- Revenue This Year
- TLSA N/A
- AVTX N/A
- Revenue Next Year
- TLSA N/A
- AVTX N/A
- P/E Ratio
- TLSA N/A
- AVTX N/A
- Revenue Growth
- TLSA N/A
- AVTX N/A
- 52 Week Low
- TLSA $0.63
- AVTX $3.39
- 52 Week High
- TLSA $1.91
- AVTX $16.00
- Technical
- Relative Strength Index (RSI)
- TLSA 48.43
- AVTX 54.89
- Support Level
- TLSA $1.43
- AVTX $4.63
- Resistance Level
- TLSA $1.81
- AVTX $5.02
- Average True Range (ATR)
- TLSA 0.09
- AVTX 0.27
- MACD
- TLSA -0.02
- AVTX 0.00
- Stochastic Oscillator
- TLSA 18.53
- AVTX 72.73
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease, and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About AVTX Avalo Therapeutics Inc.
Avalo Therapeutics Inc is a clinical-stage biotechnology company focused on the treatment of immune dysregulation. The company's asset is AVTX-009, an anti-IL-1B monoclonal antibody ("mAb"), targeting inflammatory diseases. Avalo's pipeline also includes quisovalimab (anti-LIGHT mAb) and AVTX-008 (BTLA agonist fusion protein).